chevron_leftBack
As of 24 April 2025, Jiangsu Hengrui Medicine Co., Ltd. has a market cap of $44.58B USD, ranking #447 globally and #35 in China. It ranks #44 in the Healthcare sector, and #16 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$44.58BUSD
324.86B CNY
Enterprise Value
$41.23BUSD
300.45B CNY
Revenue (TTM)
$3.84BUSD
27.98B CNY
EBITDA (TTM)
$987.26MUSD
7.19B CNY
Net Income (TTM)
$869.57MUSD
6.34B CNY
EBITDA Margin
26%
Profit Margin
23%
PE Ratio
51.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Hong Bin Dai
open_in_new
Employees
20,238
Founded
1970
Website
hengrui.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.2% | 4.3% | 14% | 15% | 0.5% | 22% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
600276
江苏恒瑞医药股份有限公司 Class A
ISIN: CNE0000014W7
Shares Out.:
Shares Outstanding:
6.349B1
Shares Float:
3.231B2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
51.09 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; training; investment advisory; technology development; project; information; and investing services, as well as the import and export of pharmaceutical products. Jiangsu Hengrui Medicine Co., Ltd. was founded in 1970 and is headquartered in Lianyungang City, China.
